197 related articles for article (PubMed ID: 20073576)
1. Epidermal growth factor receptor signaling in nonsmall cell lung cancer.
Ganti AK
Cancer Invest; 2010 Jun; 28(5):515-25. PubMed ID: 20073576
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; BarĂ³n A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
3. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
Haura EB; Zheng Z; Song L; Cantor A; Bepler G
Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Chang MH; Ahn HK; Lee J; Jung CK; Choi YL; Park YH; Ahn JS; Park K; Ahn MJ
Cancer; 2011 Jan; 117(1):143-51. PubMed ID: 20803614
[TBL] [Abstract][Full Text] [Related]
5. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F
J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392
[TBL] [Abstract][Full Text] [Related]
6. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.
Morgillo F; Woo JK; Kim ES; Hong WK; Lee HY
Cancer Res; 2006 Oct; 66(20):10100-11. PubMed ID: 17047074
[TBL] [Abstract][Full Text] [Related]
7. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
8. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
9. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
Morgillo F; Kim WY; Kim ES; Ciardiello F; Hong WK; Lee HY
Clin Cancer Res; 2007 May; 13(9):2795-803. PubMed ID: 17473213
[TBL] [Abstract][Full Text] [Related]
10. EGFR inhibition in NSCLC: the emerging role of cetuximab.
Herbst RS
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S41-51. PubMed ID: 19780245
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression.
Friess T; Scheuer W; Hasmann M
Anticancer Res; 2006; 26(5A):3505-12. PubMed ID: 17094474
[TBL] [Abstract][Full Text] [Related]
12. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
13. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
Sequist LV; Bell DW; Lynch TJ; Haber DA
J Clin Oncol; 2007 Feb; 25(5):587-95. PubMed ID: 17290067
[TBL] [Abstract][Full Text] [Related]
14. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
Yauch RL; Januario T; Eberhard DA; Cavet G; Zhu W; Fu L; Pham TQ; Soriano R; Stinson J; Seshagiri S; Modrusan Z; Lin CY; O'Neill V; Amler LC
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8686-98. PubMed ID: 16361555
[TBL] [Abstract][Full Text] [Related]
15. Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.
Zhang J; Jia J; Zhu F; Ma X; Han B; Wei X; Tan C; Jiang Y; Chen Y
Mol Biosyst; 2012 Oct; 8(10):2645-56. PubMed ID: 22833077
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.
Gridelli C; Maione P; Bareschino MA; Schettino C; Sacco PC; Ambrosio R; Barbato V; Falanga M; Rossi A
Anticancer Res; 2010 Apr; 30(4):1301-10. PubMed ID: 20530444
[TBL] [Abstract][Full Text] [Related]
19. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
[TBL] [Abstract][Full Text] [Related]
20. EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans.
Arteaga CL
Cancer Cell; 2006 Jun; 9(6):421-3. PubMed ID: 16766261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]